Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Costantine Albany, MD
Indiana University School of Medicine, Indiana University Simon Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
- Indiana University Health Hospital
Indianapolis, Indiana, United States
- Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Mar 2016
- Primary completion
- 13 Nov 2018
- Completion
- 23 Jan 2019
- Last update posted
- 10 Dec 2019
- Registered enrollment
- 18
- Registry id
- NCT02689219
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.